Biotech News

Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2026 Results

Perspective Therapeutics (CATX)Perspective TherapeuticsEarnings

Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced systemic treatments for cancers, today provided a business update and announced results for the quarter ended September 30, 2026.

Related news

RLAYRelay Therapeutics2026-10-28 20:12 EST

Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026

MGNXMacroGenics2026-11-12 21:01 EST

MacroGenics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate Progress

LEGNLegend Biotech Corporation2026-11-10 12:00 EST

Legend Biotech Reports Third Quarter 2026 Results and Recent Highlights

CATXPerspective Therapeutics2026-11-06 01:10 EST

Perspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs

COGTCogent Biosciences2026-11-05 21:02 EST

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial Results

PRLDPrelude Therapeutics2026-11-16 12:01 EST

Prelude Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

BMEABiomea Fusion2026-11-10 21:05 EST

Biomea Fusion Reports Third Quarter 2026 Financial Results and Corporate Highlights

CATXPerspective Therapeutics2026-11-06 17:00 EST

Perspective Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from a Phase 1/2a Study in Heavily Pretreated Advanced Melanoma Patients at SITC 2026

ELVNEnliven Therapeutics2026-11-05 21:05 EST

Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update

LYELLyell Immunopharma2026-11-04 21:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026

Perspective Therapeutics

Lead-212 Radiopharmaceuticals Perspective Therapeutics develops targeted radiopharmaceuticals using the alpha-emitting isotope lead-212. Specialized targeting molecules carry radiation to cancer cells, while related imaging agents can support patient selection and dosimetry. VMT-Alpha-NET VMT-α-NET is a lead-212 radiopharmaceutical in...

Recent company news

Stock data

Close
0.78 USD
Market cap
410.57M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States